190786-44-8 | Bepotastine besilate

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$9.00	$6.00
25mg	97%	in stock	$25.00	$18.00
50mg	97%	in stock	$42.00	$29.00
100mg	97%	in stock	$52.00	$36.00
250mg	97%	in stock	$77.00	$54.00
1g	97%	in stock	$177.00	$124.00
5g	97%	in stock	$633.00	$443.00

Description

• Catalog Number: AB12301
• Chemical Name: Bepotastine besilate
• CAS Number: 190786-44-8
• Molecular Formula: C27H31ClN2O6S
• Molecular Weight: 547.0628
• MDL Number: MFCD01938491
• SMILES: OS(=O)(=O)c1ccccc1.OC(=O)CCCN1CCC(CC1)O[C@H](c1ccccn1)c1ccc(cc1)Cl

Computed Properties

• Complexity: 632
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 9

Literature

• Health-related quality of life assessed by the effect of bepotastine besilate in patients with pruritus: importance of emotions score in atopic dermatitis.

  The Journal of dermatology 20120601

• Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch.

  International archives of allergy and immunology 20120101

• Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography.

  Journal of clinical psychopharmacology 20101201

• Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate.

  Current medical research and opinion 20101001

• Oral bepotastine: in allergic disorders.

  Drugs 20100820

• Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.

  Experimental eye research 20100701

• Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20100701

• Bepotastine (bepreve)--an ophthalmic H1-antihistamine.

  The Medical letter on drugs and therapeutics 20100208

• New drugs: asenapine, iloperidone, and bepotastine besilate.

  Journal of the American Pharmacists Association : JAPhA 20100101

• Multiple H1-antihistamine-induced urticaria.

  The Journal of dermatology 20090401

• Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber).

  Expert opinion on pharmacotherapy 20090301

• Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes.

  Skin pharmacology and physiology 20090101

• Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin.

  British journal of clinical pharmacology 20080601

• Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.

  Methods and findings in experimental and clinical pharmacology 20080401

• Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice.

  International archives of allergy and immunology 20080101

• Involvement of histamine released from mast cells in acute radiation dermatitis in mice.

  Journal of pharmacological sciences 20070601

• Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice.

  European journal of pharmacology 20061010

• Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.

  Drug metabolism and disposition: the biological fate of chemicals 20060501